Intraperitoneal carboplatin and etoposide for persistent epithelial ovarian cancer: analysis of results by prior sensitivity to platinum-based regimens.
Eighteen women with epithelial ovarian cancer and small-volume disease within the peritoneal cavity at reassessment laparotomy after initial treatment with platinum-based regimens received treatment with a combination of intraperitoneal (ip) carboplatin and etoposide administration. The dose of carboplatin was fixed at 200 mg/m2 whereas the dose of etoposide was escalated in cohorts of 4 patients from 50 to 75 and eventually to 100 mg/m2. Hematologic toxicities appeared to be related to decreased renal function, and, in the last cohort of 10 patients, with prior treatment with systemic carboplatin. Because of this shift in patient population, escalations ceased and ip cisplatin was partly substituted for ip carboplatin in 5 patients. The study opened July 1988 and closed on July 1991: 8 patients are alive, with 4 enjoying progression-free survival and no clinical evidence of disease 1 to 4 years after onset of treatment. One patient is alive with no clinical evidence of disease 3+ years after a late relapse was treated with systemic carboplatin. Three other patients are alive with evidence of disease, having experienced improvements with taxol and ip floxuridine. Analysis of this small experience by pretreatment characteristics suggests that patients who are platinum sensitive and not allowed to relapse, have normal baseline CA-125s, and undergo successful secondary cytoreductive surgery may benefit from platinum-based ip therapy.
Muggia
F M
FM
Department of Medicine, University of Southern California, Los Angeles 90033.
Groshen
S
S
Russell
C
C
Jeffers
S
S
Chen
S C
SC
Schlaerth
J
J
Curtin
J
J
Morrow
C P
CP
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D002945:Cisplatin / Q000008:administration & dosage; D015331:Cohort Studies; D003404:Creatinine / Q000378:metabolism; D003520:Cyclophosphamide / Q000008:administration & dosage; D004848:Epithelium / Q000473:pathology; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007263:Infusions, Parenteral; D007668:Kidney / Q000187:drug effects; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000556:secondary; D016896:Treatment Outcome
D005047:Etoposide; D003520:Cyclophosphamide; D003404:Creatinine; D016190:Carboplatin; D002945:Cisplatin